8,490 Shares in Zoetis Inc. $ZTS Acquired by FORA Capital LLC

Key Points

• FORA Capital LLC acquired 8,490 shares of Zoetis Inc., valued at approximately $1.4 million, during the first quarter.
• Institutional investors hold 92.80% of Zoetis's stock, with significant positions modified by hedge funds including Nuveen LLC and GAMMA Investing LLC.
• Zoetis recently reported earnings of $1.76 per share, exceeding analysts' expectations, along with a revenue of $2.46 billion for the quarter.

FORA Capital LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 8,490 shares of the company's stock, valued at approximately $1,398,000.

A number of other hedge funds also recently modified their holdings of ZTS. Nuveen LLC purchased a new position in shares of Zoetis during the first quarter valued at $616,375,000. Sarasin & Partners LLP acquired a new stake in Zoetis during the 1st quarter worth about $339,111,000. Mackenzie Financial Corp grew its stake in Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after acquiring an additional 1,782,110 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after purchasing an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC lifted its position in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company's stock.

Zoetis Stock Down 0.0%

Zoetis stock opened at $155.12 on Wednesday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The firm's fifty day simple moving average is $153.53 and its 200-day simple moving average is $158.28. The company has a market capitalization of $68.75 billion, a P/E ratio of 26.70, a P/E/G ratio of 2.49 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.